Ibuprofen arginate retains eNOS substrate activity and reverses endothelial dysfunction: implications for the...

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Inflammation Research

Background:

• Nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, inhibit cyclooxygenase-2 (COX-2) for anti-inflammatory effects.
• NSAID use is linked to cardiovascular risks, potentially due to COX-2 inhibition in the vasculature and kidneys, and elevated levels of the hormone asymmetric dimethylarginine (ADMA).
• L-arginine can counteract the cardiotoxic effects of ADMA.

Purpose of the Study:

• To investigate whether ibuprofen arginate can simultaneously inhibit COX-2 and preserve the nitric oxide (NO) pathway.
• To explore the potential of ibuprofen arginate to mitigate cardiovascular risks associated with NSAID use.

Main Methods:

• Compared the COX-2 inhibitory activity of ibuprofen arginate and ibuprofen sodium in mouse and human COX-2.
• Assessed the ability of ibuprofen arginate to act as a substrate for nitric oxide synthase (NOS).
• Evaluated the reversal of ADMA and N^G-nitro-l-arginine methyl ester-induced inhibition of NOS in vitro and in vivo.

Main Results:

• Ibuprofen arginate demonstrated similar COX-2 inhibition compared to ibuprofen sodium.
• Only ibuprofen arginate served as a substrate for NOS.
• Ibuprofen arginate, but not ibuprofen sodium, reversed NOS inhibition by ADMA and N^G-nitro-l-arginine methyl ester in macrophages, aorta, and blood pressure.

Conclusions:

• Ibuprofen arginate acts as both a COX-2 inhibitor and a NOS substrate in a single preparation.
• This dual action may counteract cardiovascular risks linked to renal COX-2 inhibition and increased ADMA.
• Ibuprofen arginate represents a potentially significant advancement in NSAID development for improved cardiovascular safety.